Welcome back to Endpoints Weekly! We unveiled our 2026 Women in Biopharma special project on Monday. Our team pored through nearly 200 nominations to reach this year’s list of 20 ...

Pancreatic cancer patients with the most common KRAS mutation appeared to have a lower response rate than the overall patient ...

Brent Saun­ders was think­ing a lot about skin­care and longevi­ty dur­ing the Covid-19 pan­dem­ic, short­ly af­ter he fin­ished up the more than $60 bil­lion sale of Al­ler­gan to Ab­b­Vie. Af­ter ...

The phar­ma in­dus­try is yet again tak­ing the gov­ern­ment to court over its lat­est ef­fort to con­trol US drug prices. Last week, the Trump ad­min­is­tra­tion fi­nal­ized a demon­stra­tion ...

IPOs on Nasdaq, backed by Eli Lilly, focusing on Treg science for autoimmune disorders. Pipeline includes TRB-061 and a CD30 agonist for IBD.

City Therapeutics eyes $158M IPO; Iambic Therapeutics targets $135M; Alchemist Capital launches with $100M; Life Biosciences ...

Ultragenyx sells a rare pediatric disease PRV for $210M, one of 2026's priciest voucher deals, and plans to monetize a second ...

PhRMA says FDA will get money it can spend only on hiring and keeping staff, to restore reviewer levels after the HHS layoffs ...

Curium prices Bexlutry, its copycat of Novartis’ radioligand Lutathera, at $63,524 per infusion, about 5% below the original.

WHO releases preeclampsia roadmap; Comanche, DiaMedica, Avilar & ProFound developing treatments; Eli Lilly exploring the ...

Biohaven licenses pan-IgG degraders to Ono for $80M; UK pulls Ixchiq; ADC raises $86.6M; BMS Zenbexus Phase 3 win; Pfizer ...

Chan Zuckerberg Biohub launches $1.8B Virtual Biology Initiative with Meta, Google DeepMind, Isomorphic Labs, DOE, and NIH to ...